Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.

Publication

Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.

Journal Paper/Review - Feb 25, 2022

Zeng Linan, Walsh Michael, Guyatt Gordon, Siemieniuk Reed A C, Collister David, Booth Michelle, Brown Paul, Farrar Lesha, Farrar Mark, Firth Tracy, Fussner Lynn A, Kilian Karin, Little Mark A, Mavrakanas Thomas A, Mustafa Reem A, Piram Maryam, Stamp Lisa K, Xiao Yingqi, Lytvyn Lyubov, Agoritsas Thomas, Vandvik Per O, Mahr Alfred

Citation

Zeng L, Walsh M, Guyatt G, Siemieniuk R, Collister D, Booth M, Brown P, Farrar L, Farrar M, Firth T, Fussner L, Kilian K, Little M, Mavrakanas T, Mustafa R, Piram M, Stamp L, Xiao Y, Lytvyn L, Agoritsas T, Vandvik P, Mahr A. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ 2022; 376:e064597.

Type

Journal Paper/Review (English)

Journal

BMJ 2022; 376

Publication Date

Feb 25, 2022

Issn Electronic

1756-1833

Pages

e064597

Brief description/objective

What is the role of plasma exchange and what is the optimal dose of glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)? This guideline was triggered by the publication of a new randomised controlled trial.